Register With Data From Patients With the Diagnosis of a Peritoneal Surface Malignancy, for Which Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) is Performed
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 125
- Locations
- 2
- Primary Endpoint
- To improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.
Study Overview
Brief Summary
The purpose of this study is to register the follow-up data of patients who, because of a peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC.
Detailed Description
To register the follow-up data of patients who, because of a peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC. In this surgical intervention, the abdominal cavity is macroscopically cleared of tumor, by removing all visible tumor nodules, and is subsequently rinsed with hyperthermic (heated) chemotherapy, aiming to destroy all residual invisible tumor cells that might have stayed behind after the debulking.
The eventual aim of this procedure is to improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy
Exclusion Criteria
- Not provided
Arms & Interventions
Registry
Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy
Outcomes
Primary Outcomes
To improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.
Time Frame: Follow-up over a time period of at least 5 years
Secondary Outcomes
No secondary outcomes reported